Herb Greenberg is the editor of Herb Greenberg's Reality Check, a subscription newsletter designed to help investors better manage risk. He writes a daily blog for TheStreet's main free website and contributes to its Real Money's "Columnist Conversation" column as well as being a regular contributor for CNBC.
Greenberg has been a financial journalist for more than 30 years, working most recently as a senior stocks commentator on CNBC's Business Day programming and on CNBC.com. He was also co-president of Greenberg Meritz Research & Analytics. He is a former weekend investor columnist for The Wall Street Journal and a former senior columnist for MartketWatch.
Prior to joining MarketWatch, Greenberg was senior columnist for TheStreet.com. He previously spent 10 years as the "Business Insider" columnist for the San Francisco Chronicle and nearly seven years as Fortune magazine's monthly "Against the Grain" columnist.
He also was the New York financial correspondent for the Chicago Tribune and a financial reporter in its Chicago newsroom. Greenberg has held various positions at other media outlets including Crain's Chicago Business and the St. Paul Pioneer Press.
Greenberg holds a bachelor's degree in journalism from the University of Miami.
Follow Herb Greenberg on Twitter
The headlines Monday trumpet HSBC's sharp improvement in second-quarter profits. But that isn't impressing Peter Atwater, president of the Financial Insyghts, a financial services consulting firm.
The credit card company reported that its “core” earnings of $1.38 per share, which were 6 cents ahead of expectations. Here’s what it didn’t say: that the $1.38 included 18 cents from the reversal or “release” of reserves tied to an accounting change. The accounting change, in essence, involves pulling securitized assets on balance sheet from off-balance sheet.
If you read Google's earnings release yesterday, you would have seen this under cash: That the company's cash balance of $30 billion included cash collateral of $2.9 billion that “we received in connection with our securities lending program..." Did they say securities lending program?
Carlyle’s deal to buy NBTY, the vitamin company, for $3.8 billion stopped me in my tracks. NBTY has been a long-standing tug-of-war stock between the longs and shorts.